Results 81 to 90 of about 50,152 (259)

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings

BMC Primary Care
Background Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death.
Stephanie A. Hooker, Colleen Starkey, Gavin Bart, Rebecca C. Rossom, Sheryl Kane, Anthony W. Olson   +5 more
doaj   +1 more source

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, EarlyView.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Donepezil reverses buprenorphine-induced central respiratory depression in anesthetized rabbits

Biological Research, 2009
Buprenorphine is a mixed opioid receptor agonist-antagonist used in acute and chronic pain management. Although this agent's analgesic effect increases in a dose-dependent manner, buprenorphine-induced respiratory depression shows a marked ceiling effect
SHIGEKI SAKURABA, MIKI TSUJITA, HIROFUMI ARISAKA, JUNZO TAKEDA, KAZUICHI YOSHIDA, SHUN-ICHI KUWANA   +5 more
doaj  

Prenatal opioid exposure, and health, social and educational outcomes for school‐aged children: A systematic review

Addiction, EarlyView.
Abstract Background and aims Recent decades have seen a rise in the number of pregnancies exposed to opioids. Whilst evidence of the impact of such exposure on pregnancy and infant outcomes is fairly robust, the impact of prenatal opioid exposure (POE) on longer‐term outcomes for children and young people remains unclear.
Louise Marryat, Dawood Gashgari, Shona Shinwell, Vicky Mitchell, Catriona Connell, Gale Macleod, Senga Robertson, Anne Whittaker, Alison McFadden   +8 more
wiley   +1 more source

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, EarlyView.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden

Addiction, EarlyView.
Abstract Background/aims Take‐home naloxone (THN) programmes have been introduced in many European countries to provide non‐medically trained people who are likely to witness an opioid overdose, including people who use opioids, with a naloxone kit and training.
Nicola Metrebian, Teodora Dascal, Clare Mackie, Rose Tinch‐Taylor, Ben Carter, Joanne Neale, Mariana Gonzalez Utrilla, Ed Day, Joar Guterstam, Kirsten Horsburgh, Martin Kåberg, Mike Kelleher, Soraya Mayet, Josie Smith, Desiree Eide, Elin Holmén, Rebecca McDonald, Stephen Parkin, Henrik Thiesen, John Strang, NalPORS Research Team, Dean Acreman, Shabana Akhtar, Louise Aitken, Martin Anderson, James Cassidy, Sarah Cosgrove, Jo Grayer, Michelle Hughes, Louise Horn, Anika Miah, John Pratt   +31 more
wiley   +1 more source

Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation

Addiction, EarlyView.
Abstract Aims To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative ...
Vivienne Y. Zhou, Nadia Fairbairn, Jingxin Lei, Rupinder Brar, Paxton Bach, M. Eugenia Socias   +5 more
wiley   +1 more source

Factors associated with readmission to residential treatment among clients transitioned from detoxification services in Alberta, Canada

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Readmission to residential treatment increases healthcare costs, strains publicly funded systems, and may not adequately meet clients' needs. This study examined rates and predictors of readmission to residential treatment among clients transitioned from detoxification services.
Abreham Mekonnen
wiley   +1 more source

Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study

Addiction Science & Clinical Practice
Background Buprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals.
J. Luke Engeriser, Thomas Hutch, Crystal L. Smith, Zach Orme, Evan Chavers, Lucinda A. Grande   +5 more
doaj   +1 more source